checkAd

     253  0 Kommentare Apexigen Announces Phase 2 Data Evaluating Sotigalimab, its CD40 Agonist Antibody, in Combination with Doxorubicin in Patients with Advanced Soft Tissue Sarcoma Presented at the American Society of Clinical Oncology (ASCO) 2023 Annual Meeting - Seite 4

    Investor Contact:
    Bruce Mackle
    LifeSci Advisors
    +1-646-889-1200
    bmackle@lifesciadvisors.com

    Lesen Sie auch

    Apexigen Contact:
    William Duke
    Chief Financial Officer
    Apexigen, Inc.
    +1-650-931-6236
    ir@apexigen.com



    globenewswire
    0 Follower
    Autor folgen
    RSS-Feed abonnieren

    Weitere Artikel des Autors

    Seite 4 von 4
    Verfasst von globenewswire
    Apexigen Announces Phase 2 Data Evaluating Sotigalimab, its CD40 Agonist Antibody, in Combination with Doxorubicin in Patients with Advanced Soft Tissue Sarcoma Presented at the American Society of Clinical Oncology (ASCO) 2023 Annual Meeting - Seite 4 - Marked increases in overall survival observed across soft tissue sarcoma patients - - Demonstrated improvement of median progression free survival in patients with dedifferentiated liposarcoma (DDLPS) - - DDLPS expansion cohort enrolling to …